Metraipolis › archive › dc_bc3ca301b176

Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now? — Europe PMC PMID:40862721

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40862721
DOI: 10.3390/cells14161242
License (as archived): solo-consultazione
Archived: 2026-11-10T17:29:15.645Z
SHA-256 of the archived text: 37b8a632009de2459970f54c5f5d89f70fbb642948f8fcec07f694734f396c03
Stable URL of this page: https://metraipolis.com/documento/dc_bc3ca301b176

How to cite

Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now? — Europe PMC PMID:40862721 — Europe PMC (en), https://europepmc.org/article/MED/40862721 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bc3ca301b176 (Metraipolis archive dc_bc3ca301b176, sha256 37b8a632009de2459970f54c5f5d89f70fbb642948f8fcec07f694734f396c03)

BibTeX

@misc{dcbc3ca301b176,
  title = {Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now? — Europe PMC PMID:40862721},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40862721},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bc3ca301b176; sha256 37b8a632009de2459970f54c5f5d89f70fbb642948f8fcec07f694734f396c03},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40862721. Agents can read the archived copy with the MCP tool read_document.